Coronavirus Updates

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RNA Interference Drug Fitusiran Effective in both Hemophilia A and B

Publish date:: August 7, 2019

Key clinical point: The RNA interference drug fitusiran appears to be safe and efficacious in hemophilia A and B.

Major finding: Once-monthly fitusiran therapy was associated with a reduction in median annualized bleeding rates from 42.00 to 1.04 in patients with inhibitors.

Study details: A phase 2, open-label extension study in 34 individuals with hemophilia A and B, with and without inhibitors, who were treated with fitusiran for at least 2 years.

Disclosures: The study was funded by Sanofi Genzyme and Alnylam Pharmaceuticals, and six authors were employees of Sanofi Genzyme. Dr. Pasi reported financial relationships with pharmaceutical companies, including Alnylam.

Citation:

Pasi J et al. 2019 ISTH Congress, Abstract OC 11.3.

This Week's Must Reads

How prostate cancer treatments affect quality of life,

Study finds no link between platelet count, surgery bleed risk in cirrhosis,

PEGPH20 strikeout raises doubts about stroma-targeting agents in pancreatic cancer,

ACS disagrees with CDC on HPV vaccination in adults,

Better continence rate gives robotic prostatectomy the edge,

Must Reads in Bleeding Disorders

Large cohort study: Bevacizumab safe, effective for severe HHT bleeds,

SPK-8011 AAV-mediated Hemophilia A therapy shows stability, durability,

Liver biopsies show persistent FVIII after gene therapy for hemophilia A,

Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders,

Subcutaneous hep A vaccination as effective as intramuscular for bleeding disorder patients,